[
    [
        {
            "time": "2023-04-15",
            "original_text": "一季报又有重磅持股信息，刘格菘“独宠”这家公司",
            "features": {
                "keywords": [
                    "一季报",
                    "刘格菘",
                    "持股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "一季报又有重磅持股信息，刘格菘“独宠”这家公司",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-16",
            "original_text": "安信证券：健帆生物(300529.SZ)血液灌流权威学术体系搭建再下一城，维持“买入-A”评级",
            "features": {
                "keywords": [
                    "安信证券",
                    "健帆生物",
                    "血液灌流",
                    "买入-A"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安信证券：健帆生物(300529.SZ)血液灌流权威学术体系搭建再下一城，维持“买入-A”评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-17",
            "original_text": "健帆生物(300529.SZ)一季度归母净利同比增长53.62%至2.83亿元",
            "features": {
                "keywords": [
                    "健帆生物",
                    "归母净利",
                    "同比增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529.SZ)一季度归母净利同比增长53.62%至2.83亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-04-18",
            "original_text": "健帆生物(300529.SZ)一季度净利润升53.62%至2.83亿元",
            "features": {
                "keywords": [
                    "健帆生物",
                    "净利润",
                    "增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529.SZ)一季度净利润升53.62%至2.83亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-04-19",
            "original_text": "健帆生物：一季度净利润同比增长53.62%",
            "features": {
                "keywords": [
                    "健帆生物",
                    "净利润",
                    "增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物：一季度净利润同比增长53.62%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-20",
            "original_text": "高瓴资本概念股普遍下滑，公牛集团、泰格医药、健帆生物、凯莱英领跌",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "健帆生物",
                    "下滑",
                    "领跌"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "高瓴资本概念股普遍下滑，公牛集团、泰格医药、健帆生物、凯莱英领跌",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-04-21",
            "original_text": "2020年财报亮眼，股权激励下业绩或再提速，血液灌流器龙头健帆生物势不可挡",
            "features": {
                "keywords": [
                    "健帆生物",
                    "财报",
                    "股权激励",
                    "业绩提速"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2020年财报亮眼，股权激励下业绩或再提速，血液灌流器龙头健帆生物势不可挡",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2023-04-22",
            "original_text": "近一周22家公司获机构扎堆调研！",
            "features": {
                "keywords": [
                    "机构调研",
                    "公司"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合行业"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "近一周22家公司获机构扎堆调研！",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-23",
            "original_text": "医药与健康护理行业周报：年报一季报相继披露 看好业绩确定性高的医药白马",
            "features": {
                "keywords": [
                    "医药",
                    "健康护理",
                    "年报",
                    "一季报",
                    "业绩确定性"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药与健康护理行业周报：年报一季报相继披露 看好业绩确定性高的医药白马",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-04-24",
            "original_text": "安信证券--健帆生物：肾病产品卫生经济学研究数据发布，血液灌流权威学术体系搭建再下一城【公司研究】",
            "features": {
                "keywords": [
                    "安信证券",
                    "健帆生物",
                    "肾病产品",
                    "卫生经济学",
                    "血液灌流"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安信证券--健帆生物：肾病产品卫生经济学研究数据发布，血液灌流权威学术体系搭建再下一城【公司研究】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]